Koch Institute

Exploiting cancer cells' weaknessesTeam identifies potential drugs that enhance stress caused by too many chromosomes.

Nano-sized vaccinesNew MIT nanoparticles could lead to powerful vaccines for HIV and other diseases.

Vander Heiden wins cancer innovation awardAwarded $450,000 grant over three years

A new approach to bladder-disease treatmentImplanted device can release slow, steady dose of medicine over extended period, removing the need for repeated procedures.

Timing is everything for cancer protein p53Biologists find that restoring the gene for p53 can slow the spread of advanced lung tumors, but doesn’t help early-stage cancers.

Slideshow: the Koch Institute transforms East Campus environsCompletion of cancer-research building opens green space for community use and creates vibrant streetscape.

Direct deliveryCancer scientists believe nanoparticles could accurately target tumors, avoiding side effects.

Using the body’s own defenses to combat cancerBy engineering T cells to attack tumors, researchers hope to add a new weapon to their cancer-fighting arsenal.

Turning off cancer genesRNA interference holds much promise as a cancer treatment, but technical challenges remain.

A better way to target tumorsIn spite of slow progress toward targeting cancer drugs to individual patients, hope remains.

A new target for cancer drugsShutting down an enzyme that responds to DNA damage could boost the effects of traditional chemotherapy.

Cancer’s hiding spots revealedDiscovery that tumor cells can escape from chemotherapy could lead to new treatments that prevent relapse.

New Koch Institute building to open soonResearchers will start moving into the 365,000-square-foot building next week.

Surprising similarities between human and zebrafish tumorsNew finding that tumor cells in both species have too many chromosomes could help pinpoint genes that drive cancer development.

An unexpected twist in cancer metabolismA cancer-cell quirk could be exploited to develop new drugs that starve tumors.

A pharmacy on the back of a cellDrugs encapsulated in new MIT nanoparticles can hitch a ride to tumors on the surface of immune-system cells.

MIT’s Koch Institute in strategic partnership with Ortho-McNeil-Janssen PharmaceuticalsOrganizations will collaborate in multiple areas of oncology research and technology development.

Tackling cancer on a new frontNew program at MIT’s Koch Institute targets the growing cancer problem in India.

Rapid analysis of DNA damage now possibleTechnology offers a new way to test potential cancer drugs, detect effects of hazardous agents in our environment.

Why cancer drugs lose their powerMIT biologists show how tumors can become resistant to the commonly used chemotherapy drug cisplatin.

Weighing the cellMIT biological engineers devise a way to measure, for the first time, how single cells accumulate mass.

To starve a tumorMIT’s Matthew Vander Heiden is part of a new generation of cancer researchers trying to exploit cancer cells’ strange metabolism.

New and improved RNA interferenceResearchers use RNA interference to silence multiple genes at once. The advance, which one expert calls a ‘substantial breakthrough,’ could lead to new treatments for liver diseases.

Explained: RNA interferenceExploiting the recently discovered mechanism could allow biologists to develop disease treatments by shutting down specific genes.

Nanoparticles for gene therapy improveMIT team’s nanoparticles could become a safer alternative to gene therapy delivered by viruses.

Possible origins of pancreatic cancer revealedTumors can arise from different cell types in the pancreas, depending on the circumstances, according to MIT cancer biologists.

Cancer research gets physical5-year grant from the National Cancer Institute will fund projects by physicists that give a new view of cancer cells.

Protein is linked to lung cancer developmentDrugs that inhibit the protein, which normally helps defend cells from infection, could target tumors in certain lung cancer patients.

Two from MIT elected to the Institute of MedicineProfessor of Economics Amy Finkelstein and Tyler Jacks, director of the Koch Institute, join arm of the National Academies of Science.